US FDA Quashes Citizen Petition Against Bluebird’s Zynteglo That Cited Patent, Safety Concerns

 
• By Brenda Sandburg
  
Blood gene therapy
FDA rejects petition seeking to delay approval of bluebird bio's blood disorder gene therapy • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Cell & Gene Therapies

More from Advanced Technologies